Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26662607 | 1.00 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGCYP1A1 | |
| SCHEMBL26662600 | 1.00 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGCYP1A1 | |
| SCHEMBL27146895 | 0.86 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CDPIK3CGCYP1A1 | |
| SCHEMBL30742619 | 0.86 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CDPIK3CGCYP1A1 | |
| SCHEMBL26887561 | 0.86 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CDPIK3CGCYP1A1 | |
| SCHEMBL26662547 | 0.85 | PIK3CA (0.44) | PIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL30584359 | 0.85 | PIK3CA (0.44) | PIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL26662554 | 0.85 | PIK3CA (0.44) | PIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL30584309 | 0.85 | PIK3CA (0.54) | PIK3CAPIK3CBPIK3CDPIK3CGCYP1A1 | |
| SCHEMBL26662590 | 0.85 | PIK3CA (0.54) | PIK3CAPIK3CBPIK3CDPIK3CGCYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514784-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119301106-A | Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PIK3CB 16/4885PIK3CD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.